10x Genomics 3Q 2026: Revenue $150.67M, EPS ($0.15) — 10-Q Summary
10x Genomics reported 3Q 2026 revenue of $150.67M, up 1% YoY. Net loss narrowed to $19.43M, with EPS at ($0.15). Consumables revenue rose 5%, while instrument revenue fell 43%. Gross margin improved to 75%. The company acquired Proteintech Genomics for $6.1M.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh quantitative data that can adjust valuation models, especially the improved gross margin and loss narrowing, while instrument sales weakness may temper upside.
Market read
The filing offers new earnings data for a mid-cap biotech, presenting a modest trading opportunity based on mixed performance signals.
What to watch
Potential impact of the recent acquisition of PTG on future proteomics revenue and the early-stage rollout of the Atera platform.
Background
The article summarizes the 10-Q filing for 10x Genomics, highlighting key financial metrics and recent strategic moves such as the Atera platform launch and PTG acquisition.
Ticker impact
10x Genomics reported Q3 2026 revenue of $150.67M, a 1.1% YoY increase, and narrowed net loss, marking the first public disclosure of these results.
likely modest upward pressure as investors digest improved profitability metrics, offset by concerns over instrument revenue decline
Earnings beat on top line and loss reduction are fresh data; however, mixed segment performance suggests limited catalyst strength.
Market effects
Slightly positive for the broader genomics and life-sciences equipment sector as revenue growth signals demand, but instrument slowdown may raise caution.
Primarily U.S. market impact; limited immediate effect on international peers.
Modest relevance; the data may influence biotech investors but unlikely to shift broader market sentiment.
Counterpoint
The decline in instrument revenue and upcoming margin compression could signal a longer-term slowdown, suggesting a short or defensive stance.
Key entities
- company10x Genomics, Inc.
Life-sciences technology company reporting Q3 2026 results.
- companyPTG (Proteintech Genomics)
Acquired by 10x Genomics to expand proteomics capabilities.
